Characteristic Neuroimaging in Patients with Tumefactive Demyelinating Lesions Exceeding 30 mm

Journal of Neuroimaging

Volumn 21, Issue 2, 2011, Pages

  Kiriyama, Takao ^a   Kataoka, Hiroshi ^a   Taoka, Toshiaki ^a   Tonomura, Yasuyo ^a   Terashima, Mari ^a   Morikawa, Masami ^a   Tanizawa, Emi ^a   Kawahara, Makoto ^a   Furiya, Yoshiko ^a   Sugie, Kazuma ^a   Kichikawa, Kimihiko ^a   Ueno, Satoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Demyelination; MRI; Multiple sclerosis; Neuroimaging; Tumefactive demyelinating lesion

Indexed keywords

CYCLOSPORIN A; IMMUNOGLOBULIN; INTERFERON; METHOTREXATE; N ACETYLASPARTIC ACID; STEROID;

ADOLESCENT; ADULT; ARTICLE; BRAIN ANGIOGRAPHY; CLINICAL FEATURE; CONTROLLED STUDY; DEMYELINATING DISEASE; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; IMAGE ENHANCEMENT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TUMEFACTIVE DEMYELINATING LESION; VEIN DILATATION;

ADOLESCENT; ADULT; BRAIN CHEMISTRY; BRAIN DISEASES; CONTRAST MEDIA; DEMYELINATING DISEASES; DIAGNOSIS, DIFFERENTIAL; DISABILITY EVALUATION; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 79953047330     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2010.00502.x     Document Type: Article

References (32)

1. Dagher AP, Smirniotopoulos J. Tumefactive demyelinating lesions. Neuroradiology 1996;38:560-565.
2. Lucchinetti CF, Gavrilova RH, Metz I, et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008;131:1759-1775.
3. Malhotra HS, Jain KK, Agarwal A, et al. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler 2009;15:193-203.
4. Kim DS, Na DG, Kim KH, et al. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging. Radiology 2009;251:467-475.
5. Saindane AM, Cha S, Law M, et al. Proton MR spectroscopy of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2002;23:1378-1386.
6. Enzinger C, Strasser-Fuchs S, Ropele S, et al. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging. Mult Scler 2005;11:135-139.
7. Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007;28:272-277.
8. Law M, Meltzer DE, Cha S. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. Neuroradiology 2002;44:986-989.
9. Polman CH, Reingold SC, Edan G. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria. Ann Neurol 2005;58:840-846.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
11. Nyquist PA, Cascino GD, McClelland RL, et al. Incidence of seizures in patients with multiple sclerosis: a population-based study. Mayo Clin Proc 2002;77:910-912.
12. Nakashima I, Fujihara K, Sato S, et al. Oligoclonal IgG bands in Japanese patients with multiple sclerosis. A comparative study between isoelectric focusing with IgG immunofixation and high-resolution agarose gel electrophoresis. J Neuroimmunol 2005;159:133-136.
13. Lunding J, Midgard R, Vedeler CA. Oligoclonal bands in cerebrospinal fluid: a comparative study of isoelectric focusing, agarose gel electrophoresis and IgG index. Acta Neurol Scand 2000;102:322-325.
14. Lassmann H. Recent neuropathological findings in MS-implications for diagnosis and therapy. J Neurol 2004;251:IV2-IV5. Review.
15. Hart MN, Earle KM. Haemorrhagic and perivenous encephalitis: a clinical pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975;38:585-591.
16. Masdeu JC, Quinto C, Olivera C, et al. Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology 2000;54:1427-1433.
17. Masdeu JC, Moreira J, Trasi S, et al. The open ring. A new imaging sign in demyelinating disease. Neuroimaging 1996;6:104-107.
18. Dale RC, Branson JA. Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis Arch Dis Child 2005;90:636-639.
19. Geurts JJ, Barkhof F. Gray matter pathology in multiple sclerosis. Lancet Neurol 2008;7:841-851.
20. Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. Acortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005;236:254-260.
21. Arnold DL, Matthews PM, Francis GS, et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-241.
22. Herminghaus S, Pilatus U, Möller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002;15:385-392.
23. Castillo M, Kwock L, Scatliff J, et al. Proton MR spectroscopy in neoplastic and non-neoplastic brain disorders. Magn Reson Imaging Clin N Am 1998;6:1-20.
24. Zivadinov R, Minagar A. Evidence for gray matter pathology in multiple sclerosis: a neuroimaging approach. J Neurol Sci 2009;282:1-4.
25. Ge Y, Zohrabian VM, Grossman RI. Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. Arch Neurol 2008;65:812-816.
26. Zamboni P, Menegatti E, Galeotti R, et al. The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. J Neurol Sci 2009;282:21-27.
27. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
28. Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993;33:18-27.
29. Truyen L, van Waesberghe JH, van Walderveen MA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476.
30. Rovaris M, Barkhof F, Calabrese M, et al. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology 2009;72:1693-1701.
31. Poser S, Lüer W, Bruhn H, et al. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 1992;86:579-585.
32. Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009;15:159-173.